{"gene":"PRRX1","run_date":"2026-04-28T19:45:45","timeline":{"discoveries":[{"year":2012,"finding":"PRRX1 is an EMT inducer that confers migratory and invasive properties on carcinoma cells; loss of PRRX1 is required for metastatic colonization in vivo, with reversion to epithelial phenotype concomitant with acquisition of stem cell properties, demonstrating that PRRX1 uncouples EMT and stemness.","method":"In vivo metastasis assays, loss-of-function (knockdown) and gain-of-function in cancer cell lines, EMT marker analysis","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 — clean KO/KD with defined cellular phenotype in vitro and in vivo, replicated across multiple cancer models","pmids":["23201163"],"is_preprint":false},{"year":1999,"finding":"In AML with t(1;11)(q23;p15), NUP98 is fused in-frame to PMX1 (PRRX1); the fusion protein retains the PMX1 homeodomain and the N-terminal GLFG-rich NUP98 transcriptional activation domain, suggesting the fusion acts as an oncogenic transcription factor by upregulating PMX1 homeodomain-driven transcription.","method":"Molecular cloning, RT-PCR, translocation breakpoint sequencing","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 3 — molecular characterization of fusion transcript, single lab, no functional reconstitution","pmids":["10397741"],"is_preprint":false},{"year":2006,"finding":"The NUP98-PMX1 fusion protein trans-represses PMX1/SRF-mediated c-FOS activation by recruiting histone deacetylase 1 (HDAC1) via its FG repeat domains; the FG domains also bind CBP (a coactivator), giving the fusion dual trans-activator and trans-repressor activity.","method":"Luciferase reporter assays, co-immunoprecipitation, protein biochemical assays, molecular cloning","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — reciprocal co-IP and functional reporter assays with multiple orthogonal methods in one study","pmids":["16651408"],"is_preprint":false},{"year":1997,"finding":"Phox1 (PRRX1 human ortholog) activates the c-fos serum response element (SRE) by interacting with serum response factor (SRF); residues on helices 1 and 2 of the homeodomain (not required for DNA binding) mediate contact with an accessory factor, while major-groove DNA contact is also required for SRE activation in vivo.","method":"Detailed homeodomain mutagenesis, in vivo transcription assays, domain-swap experiments","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 — systematic mutagenesis with functional in vivo validation, rigorous mechanistic dissection","pmids":["9343429"],"is_preprint":false},{"year":1997,"finding":"Phox1/MHox (PRRX1) overexpression does not diminish YY1-mediated repression of CArG elements, indicating that Phox1 transcriptional activation at the SRE does not operate through enhanced SRF binding; YY1 represses CArG elements by competing with SRF for overlapping binding sites.","method":"In vitro binding competition assays, serial point mutagenesis of CArG element, in vivo overexpression reporter assays","journal":"DNA and cell biology","confidence":"Medium","confidence_rationale":"Tier 1 — in vitro binding and in vivo reporter assays, single lab","pmids":["9174170"],"is_preprint":false},{"year":2008,"finding":"Leukemogenic transformation by NUP98-PMX1 requires the NUP98 GLFG domain and the DNA-binding capability of the PMX1 homeodomain, but is independent of PMX1's ability to interact with SRF; NUP98-PMX1 collaborates with Meis1 to accelerate myeloproliferative leukemia.","method":"Strategic homeodomain mutations, retroviral transduction of murine myeloid progenitors, myeloid differentiation and proliferation assays, in vivo leukemia model","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — epistasis via strategic mutagenesis and in vivo leukemia model with multiple orthogonal methods","pmids":["18604245"],"is_preprint":false},{"year":2012,"finding":"PRRX1a and PRRX1b are negative regulators of adipogenesis; they inhibit PPARγ activity and sustain expression of TGFβ2 and TGFβ3, and their knockdown enhances adipogenesis, which is phenocopied by TGFβ signaling inhibition, establishing a PRRX1→TGFβ→adipogenesis suppression axis.","method":"Stable knockdown, transient overexpression, adipogenesis assays, PPARγ reporter assays, TGFβ pathway inhibition, in vivo adipose tissue analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (KD, OE, reporter, inhibitor rescue, in vivo), single lab","pmids":["23250756"],"is_preprint":false},{"year":2011,"finding":"TNF-α stimulates a 14-fold increase in Prx1 (PRRX1) mRNA in preosteoblasts; Prx1 binds the Osterix (Osx) promoter (confirmed by ChIP), and its expression inhibits Osx and RUNX2 transcription; siRNA silencing of Prx1 abrogates TNF-mediated suppression of Osx, identifying Prx1 as an obligate mediator of TNF inhibition of osteoblast differentiation.","method":"Protein pull-down from nuclear extracts + mass spectrometry, ChIP assay, siRNA knockdown, transient expression, EMSA","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 1 — ChIP, EMSA, and siRNA rescue with multiple orthogonal methods in one study","pmids":["20683885"],"is_preprint":false},{"year":2013,"finding":"The PRRX1b isoform specifically binds the Sox9 promoter and positively regulates Sox9 expression in pancreatic cells, placing PRRX1b upstream of Sox9 in a hierarchical axis that influences acinar-ductal metaplasia; the two isoforms, PRRX1a and PRRX1b, regulate migration and invasion respectively in pancreatic cancer cells.","method":"Isoform-specific overexpression, promoter binding assays, sorted Prrx1+ cell functional assays, lineage tracing (Prrx1creERT2-IRES-GFP mice)","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods including lineage tracing, isoform-specific functional assays, and promoter binding in one study","pmids":["23355395"],"is_preprint":false},{"year":2019,"finding":"PRRX1 directly physically interacts with FOXM1 via the PRRX1A/B 200–222/217 aa region and the FOXM1 Forkhead domain; this interaction mediates cooperative transcriptional regulation of FOXM1-dependent targets and limits induction of DNA damage in pancreatic cancer cells.","method":"Co-immunoprecipitation, domain deletion mapping, luciferase reporter assays, loss-of-function and rescue experiments","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP with domain mapping and functional reporter validation, moderate evidence","pmids":["30705403"],"is_preprint":false},{"year":2021,"finding":"PRRX1 directly binds to the promoter region of the TGF-β1 gene, upregulates TGF-β1 expression, and activates the TGF-β/Smad pathway to promote stemness and angiogenesis in glioma; silencing TGF-β1 reverses PRRX1-induced malignant behaviors.","method":"Subcellular proteomics, ChIP assay (promoter binding), TGF-β1 silencing rescue experiments, in vivo knockdown","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP and rescue experiments, single lab","pmids":["34131109"],"is_preprint":false},{"year":2021,"finding":"Upon BMP stimulation, the PRRX1b (pmx-1b) isoform interacts with DNA methyltransferase DNMT3A and induces promoter methylation of PROM1 (CD133), reducing the CD133-positive glioma-initiating cell population and inhibiting tumorigenicity in vivo; the PRRX1a isoform does not have this activity.","method":"Co-immunoprecipitation of PRRX1b-DNMT3A, bisulfite sequencing of PROM1 promoter, DNMT3A silencing rescue, in vivo tumorigenicity assays","journal":"Molecular oncology","confidence":"High","confidence_rationale":"Tier 1 — Co-IP, bisulfite sequencing, and in vivo rescue with orthogonal methods in one study","pmids":["34214250"],"is_preprint":false},{"year":2017,"finding":"Suppression of PRRX1 in human embryonic stem cell-derived cardiomyocytes and embryonic zebrafish results in shortening of the atrial action potential duration, a hallmark of atrial fibrillation; a functional SNP (rs577676) in a PRRX1 enhancer alters enhancer activity and differentially regulates PRRX1 expression in human left atria.","method":"hESC-derived cardiomyocyte loss-of-function, zebrafish embryo knockdown, enhancer reporter assays in mouse atrial cell line, electrophysiological action potential measurement","journal":"Circulation. Cardiovascular genetics","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal models (hESC-CMs, zebrafish) with defined electrophysiological phenotype and enhancer functional validation","pmids":["28974514"],"is_preprint":false},{"year":2021,"finding":"PRRX1 loss-of-function mutations (p.Gln107* and p.Arg146Ile) cause familial atrial fibrillation; both mutants show significantly diminished transactivation of downstream target genes ISL1 and SHOX2 and markedly decreased ability to bind their promoters, despite normal intracellular distribution.","method":"Whole-exome sequencing, Sanger sequencing, luciferase reporter gene assays (transactivation), promoter-binding assays in HeLa cells","journal":"Journal of the American Heart Association","confidence":"Medium","confidence_rationale":"Tier 2 — functional reporter and binding assays with disease-linked mutations, single lab","pmids":["34845933"],"is_preprint":false},{"year":2022,"finding":"A variant noncoding region regulates Prrx1 expression and, when altered, predisposes to atrial arrhythmias by changing atrial electrophysiology.","method":"Functional validation of noncoding variant, in vivo electrophysiological measurements","journal":"Circulation research","confidence":"Medium","confidence_rationale":"Tier 2 — functional noncoding variant validation with electrophysiological phenotype","pmids":["34092116"],"is_preprint":false},{"year":2022,"finding":"PRRX1 is a master transcription factor that remodels super-enhancer landscapes to drive fibroblasts toward a myofibroblastic phenotype via TGF-β signaling; fibroblast-specific Prrx1 depletion induces sustained complete remission of chemotherapy-resistant cancer in genetically engineered mouse models.","method":"Super-enhancer profiling (ChIP-seq), fibroblast-specific genetic depletion in GEMM, functional in vitro assays, CAF co-culture experiments","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — super-enhancer ChIP-seq, GEMM loss-of-function, multiple orthogonal functional assays","pmids":["35589735"],"is_preprint":false},{"year":2022,"finding":"Prrx1-expressing fibroblasts are a lineage-traced pro-fibrotic subpopulation in mouse ventral dermis responsible for acute and chronic fibroses during wound repair, as demonstrated by lineage tracing and single-cell transcriptomics.","method":"Lineage tracing (Prrx1-Cre), single-cell RNA sequencing, fibrosis models","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 — lineage tracing plus single-cell transcriptomics with functional wound repair phenotype","pmids":["33176144"],"is_preprint":false},{"year":2022,"finding":"Rare Prrx1-expressing cells act as stem cells for bone, white adipose tissue, and dermis in adult mice; genetic lineage tracing and cell depletion experiments show they are indispensable for tissue homeostasis and repair, and their activity is regulated by Wnt signaling.","method":"Knock-in Cre/CreERT2 lineage tracing, cell depletion, single-cell transcriptomics, transplantation assays","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 — genetic lineage tracing, transplantation, single-cell profiling with multiple orthogonal methods","pmids":["36456880"],"is_preprint":false},{"year":2020,"finding":"Prrx1 in cancer-associated fibroblasts is critical for tuning CAF activation state, allowing dynamic switching between dormant and activated (myofibroblastic) states; Prrx1-deficient CAFs remain constitutively activated and alter tumor differentiation and gemcitabine resistance through CAF-derived hepatocyte growth factor.","method":"Genetic depletion of Prrx1 in PDAC mouse model, primary fibroblast functional assays, tumor organoid-CAF co-culture, gene expression analysis","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic depletion plus co-culture organoid experiments with defined molecular mechanism","pmids":["33007300"],"is_preprint":false},{"year":2021,"finding":"PRRX1 knockdown in HCC promotes mesenchymal-to-epithelial transition (MET) and metastatic colonization; mechanistically, PRRX1 deficiency upregulates PITX2, which increases miR-200a and miR-200b/429, which in turn suppress CTNNB1 and SLUG respectively, enabling E-cadherin re-expression.","method":"Knockdown/overexpression in HCC cell lines, microarray, animal metastasis model, pathway epistasis experiments","journal":"Cancer science","confidence":"Medium","confidence_rationale":"Tier 2 — epistasis pathway dissection with animal model, single lab","pmids":["33587761"],"is_preprint":false},{"year":2021,"finding":"RBMS3 RNA-binding protein stabilizes PRRX1 mRNA post-transcriptionally (shown by actinomycin D mRNA stability assays and RBMS3-PRRX1 mRNA interaction), and PRRX1 is required for RBMS3-mediated EMT in triple-negative breast cancer.","method":"Genome-wide mRNA stability assay (actinomycin D chase), RNA-binding protein interaction, loss-of-function rescue experiments","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — mRNA stability assay and interaction validated with rescue experiments, single lab","pmids":["34608266"],"is_preprint":false},{"year":2020,"finding":"Prrx1 CAF plasticity promotes PDAC tumor squamous subtype and gemcitabine resistance via CAF-derived hepatocyte growth factor (HGF) signaling to tumor cells.","method":"CAF-tumor organoid co-culture, gene expression subtype analysis, Prrx1 fibroblast-specific depletion in vivo","journal":"Gastroenterology","confidence":"Medium","confidence_rationale":"Tier 2 — co-culture mechanistic experiments with in vivo genetic validation, single lab","pmids":["33007300"],"is_preprint":false},{"year":2024,"finding":"Twist1 directly binds to the Prrx1 promoter to drive its expression in kidney fibroblasts; Prrx1 in turn directly binds the TNC (tenascin-C) promoter to promote fibroblast activation and kidney fibrosis, establishing a Twist1→Prrx1→TNC signaling axis.","method":"ChIP assay (Twist1 binding to Prrx1 promoter; Prrx1 binding to TNC promoter), fibroblast-specific Twist1 knockout mice, gain- and loss-of-function experiments","journal":"Kidney international","confidence":"High","confidence_rationale":"Tier 1 — ChIP demonstrating direct promoter binding at two levels of the cascade, validated with fibroblast-specific KO mouse model","pmids":["39181396"],"is_preprint":false},{"year":2022,"finding":"PRRX1 promotes resistance to temozolomide in glioma by directly binding the ABCC1 promoter and initiating its transcription, upregulating ABCC1 drug transporter expression; PRRX1 also facilitates vasculogenic mimicry formation as an extrinsic resistance mechanism.","method":"ChIP assay (PRRX1 binding to ABCC1 promoter), siRNA knockdown, in vitro and in vivo drug sensitivity assays","journal":"American journal of cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP confirming direct promoter binding, functional rescue with ABCC1 knockdown, single lab","pmids":["36119823"],"is_preprint":false},{"year":2020,"finding":"PRRX1 directly transactivates the COL6A3 promoter in adipose cells (shown by reporter assay with endogenous COL6A3 promoter), and PRRX1 knockdown reduces COL6A3 mRNA, identifying PRRX1 as a direct transcriptional regulator of COL6A3.","method":"Reporter assay (endogenous COL6A3 promoter), siRNA knockdown, stable overexpression in 3T3-L1 cells","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 — direct promoter reporter assay confirmed by KD and OE, single lab","pmids":["33214660"],"is_preprint":false},{"year":2022,"finding":"PRRX1 directly binds the MMP13 promoter (validated by luciferase reporter and ChIP assay) and activates MMP13 transcription, which in turn promotes inflammation and barrier dysfunction in colonic epithelial cells.","method":"ChIP assay, luciferase reporter assay, siRNA knockdown, overexpression, ELISA, TEER measurement","journal":"Bioengineered","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP and reporter assay with functional readouts, single lab","pmids":["34967278"],"is_preprint":false},{"year":2024,"finding":"PRRX1 promotes OLR1 expression in cancer-associated fibroblasts by recruiting active histone marks H3K27ac and H3K4me3 to the OLR1 locus, activating CAFs to support lung cancer growth and immune evasion.","method":"ChIP-seq (H3K27ac, H3K4me3), ChIP-qPCR, luciferase reporter assay, PRRX1 and OLR1 knockdown in CAFs, co-culture experiments","journal":"Cancer cell international","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP-seq and functional co-culture validation, single lab","pmids":["39010054"],"is_preprint":false},{"year":2022,"finding":"The Twist1-Prrx1-TNC positive feedback loop drives cardiac fibroblast activation to myofibroblasts; Prrx1 overexpression promotes cardiac fibroblast proliferation, migration, and myofibroblast transformation, while Prrx1 silencing attenuates TGF-β1-induced cardiac fibrosis in vitro.","method":"Overexpression and knockdown of Prrx1 in cardiac fibroblasts, TGF-β1 stimulation, proliferation and migration assays","journal":"Cell biology international","confidence":"Medium","confidence_rationale":"Tier 3 — functional KD/OE with defined phenotype and pathway placement, single lab","pmids":["36273425"],"is_preprint":false},{"year":2021,"finding":"PRRX1 directly transactivates the IL-6 promoter (confirmed by JASPAR prediction and dual-luciferase reporter assay), and IL-6 activates JAK2/STAT3 signaling to promote colorectal cancer stemness and chemoresistance.","method":"Dual-luciferase reporter assay, GSEA, Western blot, in vivo xenograft, ELISA","journal":"Journal of gastrointestinal oncology","confidence":"Medium","confidence_rationale":"Tier 2 — reporter assay with in vivo functional validation, single lab","pmids":["36636075"],"is_preprint":false},{"year":2024,"finding":"PRRX1 co-immunoprecipitates with TOP2A in malignant peripheral nerve sheath tumour (MPNST) cells; overexpressed PRRX1 directly interacts with TOP2A to cooperatively promote EMT and expression of tumour malignancy-related gene sets including mTORC1, KRAS, and SRC signaling pathways.","method":"Co-immunoprecipitation, mass spectrometry, RNA-seq, structural prediction, PRRX1 knockdown/overexpression","journal":"British journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP with mass spectrometry confirmation and transcriptomic validation, single lab","pmids":["38448751"],"is_preprint":false},{"year":2025,"finding":"PRRX1 transcriptionally activates FKBP5 (directly promoting FKBP5 expression) and thereby activates p38 MAPK signaling to drive excessive mitophagy and cardiomyocyte ferroptosis during myocardial ischemia/reperfusion injury; PRRX1 silencing is cardioprotective.","method":"siRNA knockdown, FKBP5 overexpression rescue, p38 MAPK inhibitor, in vitro OGD/R model, in vivo rat I/R model","journal":"Biochimica et biophysica acta. Molecular basis of disease","confidence":"Medium","confidence_rationale":"Tier 2 — epistasis via rescue and inhibitor experiments with in vivo validation, single lab","pmids":["40044064"],"is_preprint":false},{"year":2024,"finding":"PRRX1 directly transactivates the FAP (fibroblast activation protein) promoter (confirmed by ChIP-seq and reporter assays), establishing a PRRX1-FAP regulatory axis that drives fibroblast activation and intestinal fibrosis; fibroblast-specific Prrx1 deletion (Col1a2-Cre;Prrx1fl/fl) mitigates DNBS-induced intestinal fibrosis.","method":"Single-cell RNA-seq, ChIP-seq, dual-luciferase reporter assays, conditional knockout mouse model, colon proteomics","journal":"Journal of nanobiotechnology","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP-seq and reporter assays with conditional KO validation, single lab","pmids":["41350883"],"is_preprint":false},{"year":2022,"finding":"Mechanical stimulation enhances release of active TGF-β1, which promotes migration of Prrx1+ cells via ciliary TGF-β signaling; inhibition of TGF-β signaling, knockdown of Pallidin (blocking TGFβR2 translocation to primary cilia), or deletion of Ift88 in Prrx1+ cells all abolish mechanics-induced Prrx1+ cell migration.","method":"Single-cell RNA sequencing, in vivo mechanical stimulation models, TGFβ inhibition, Pallidin knockdown, Ift88 conditional deletion in Prrx1+ cells, migration assays","journal":"eLife","confidence":"Medium","confidence_rationale":"Tier 2 — epistasis via multiple genetic and pharmacological interventions with defined mechanosensing pathway, single lab","pmids":["35475783"],"is_preprint":false},{"year":2021,"finding":"PRRX1A isoform transcriptionally activates TGF-β expression (shown by correlation with TGF-β and TGF-β/TGFβR signaling), and PRRX1A directly binds and stabilizes SOX2 protein, promoting cancer stem cell sphere formation and self-renewal in non-small cell lung cancer.","method":"Isoform-specific overexpression and knockdown, CSC functional assays, co-immunoprecipitation (PRRX1A-SOX2 binding), in vivo mouse models","journal":"Translational lung cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — co-IP of PRRX1A-SOX2 with isoform-specific functional characterization, single lab","pmids":["32676335"],"is_preprint":false},{"year":2019,"finding":"Pre-metastatic niche-derived SDF-1 downregulates Prrx1 through STAT3 signaling in hepatocellular carcinoma cells, which in turn increases CXCR4 expression, promoting organ colonization; loss of Prrx1 was negatively correlated with increased CXCR4 in metastatic sites.","method":"Prrx1 shRNA knockdown, SDF-1 stimulation, STAT3 pathway inhibition, in vivo xenograft/metastasis assays","journal":"Journal of experimental & clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — epistasis via pharmacological inhibition and genetic KD in vivo, single lab","pmids":["31752959"],"is_preprint":false},{"year":2022,"finding":"Nicotine inhibits Prrx1 expression in pituitary stem/progenitor cells through epigenetic regulation (first intron hypermethylation of the Prrx1 gene detected by bisulfite sequencing), leading to a delayed supply of GH-producing cells.","method":"In vivo nicotine exposure in young rats, bisulfite sequencing, RT-PCR, immunohistochemistry","journal":"Growth hormone & IGF research","confidence":"Medium","confidence_rationale":"Tier 2 — bisulfite sequencing demonstrates epigenetic regulation with in vivo functional consequence, single lab","pmids":["32146343"],"is_preprint":false},{"year":2023,"finding":"Heterozygous missense variants within the PRRX1 homeodomain cause abnormal nuclear localization of the PRRX1 protein, establishing that homeodomain missense mutations impair nuclear targeting as a pathogenic mechanism in craniosynostosis.","method":"Immunofluorescence analysis of nuclear localization of wild-type vs. mutant PRRX1 proteins in patient-derived and transfected cells","journal":"Genetics in medicine","confidence":"Medium","confidence_rationale":"Tier 2 — direct localization experiment with functional consequence linking missense mutations to nuclear import defect","pmids":["37154149"],"is_preprint":false},{"year":2024,"finding":"PRRX1 promotes ANXA6 expression transcriptionally (confirmed by ChIP-PCR and dual-luciferase assay), and ANXA6 enhances PKCα/EGFR complex formation, inhibiting EGFR phosphorylation and downstream AKT and ERK1/2, thereby increasing cisplatin sensitivity in bladder cancer.","method":"ChIP-PCR, dual-luciferase assay, co-immunoprecipitation (ANXA6-PKCα-EGFR complex), mass spectrometry, immunofluorescence","journal":"Life sciences","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP and Co-IP with mechanistic pathway dissection, single lab","pmids":["39528080"],"is_preprint":false}],"current_model":"PRRX1 is a paired-related homeodomain transcription factor that directly binds gene promoters (including TGF-β1, Sox9, Osx, ABCC1, MMP13, IL-6, FAP, and FKBP5) to regulate target gene transcription; it physically interacts with co-regulators (FOXM1, TOP2A, DNMT3A, SOX2) and SRF at CArG elements, acts as a master regulator of EMT (inducing migration/invasion while uncoupling EMT from stemness), drives fibroblast-to-myofibroblast conversion via TGF-β/super-enhancer remodeling, functions as a mesenchymal stem cell marker and fate regulator for bone/adipose/dermal lineages, and suppresses adipogenesis by sustaining TGFβ ligand expression, with NUP98-PRRX1 fusion oncoproteins recruiting HDAC1 via FG repeats to act as dual transcriptional activators/repressors in leukemia."},"narrative":{"teleology":[{"year":1997,"claim":"Establishing PRRX1 as a transcription factor that activates SRE-dependent gene expression through physical interaction with SRF resolved how a homeodomain protein could regulate serum-responsive genes without acting through enhanced SRF DNA binding.","evidence":"Systematic homeodomain mutagenesis and in vivo transcription assays identifying SRF-contact residues on helices 1/2; separate competition assays showing PRRX1 does not overcome YY1-mediated CArG repression","pmids":["9343429","9174170"],"confidence":"High","gaps":["Endogenous genomic targets of PRRX1-SRF complexes not identified","Crystal structure of PRRX1-SRF complex unavailable"]},{"year":1999,"claim":"Identification of the NUP98-PRRX1 fusion in AML established that the PRRX1 homeodomain could be co-opted into an oncogenic transcription factor when fused to the NUP98 transactivation domain.","evidence":"Molecular cloning and breakpoint sequencing of t(1;11)(q23;p15) in AML patient samples","pmids":["10397741"],"confidence":"Medium","gaps":["No functional reconstitution of transformation at this stage","Endogenous target genes of the fusion not identified"]},{"year":2006,"claim":"Demonstrating that NUP98-PRRX1 recruits HDAC1 via FG repeats to repress PMX1/SRF-mediated transcription, while also binding CBP, revealed how the fusion functions as a dual activator/repressor—a key mechanistic distinction from wild-type PRRX1.","evidence":"Co-immunoprecipitation of HDAC1 and CBP with NUP98-PRRX1, luciferase reporter assays showing trans-repression of c-FOS SRE","pmids":["16651408"],"confidence":"High","gaps":["Genome-wide targets of dual regulation not mapped","Relative contribution of activation vs. repression to leukemogenesis unclear"]},{"year":2008,"claim":"Showing that NUP98-PMX1 leukemogenesis requires the GLFG domain and homeodomain DNA binding but is independent of SRF interaction clarified that the fusion transforms through homeodomain-directed target gene dysregulation rather than SRF pathway hijacking.","evidence":"Strategic homeodomain mutations disrupting SRF interaction vs. DNA binding tested in retroviral transduction of murine progenitors and in vivo leukemia models; Meis1 collaboration demonstrated","pmids":["18604245"],"confidence":"High","gaps":["Direct transcriptional targets driving transformation not identified","Mechanism of Meis1 cooperation unresolved"]},{"year":2011,"claim":"Identifying PRRX1 as an obligate mediator of TNF-α-induced suppression of osteoblast differentiation through direct binding to the Osterix promoter placed PRRX1 as a transcriptional repressor in inflammatory bone biology.","evidence":"ChIP confirming PRRX1 binding to Osx promoter, EMSA, siRNA rescue abolishing TNF-mediated Osx suppression in preosteoblasts","pmids":["20683885"],"confidence":"High","gaps":["Whether PRRX1 directly recruits co-repressors to the Osx promoter unknown","In vivo bone phenotype of PRRX1 loss in inflammatory setting not tested"]},{"year":2012,"claim":"Two landmark studies revealed PRRX1 as both an EMT inducer that uncouples migration/invasion from stemness in cancer and a suppressor of adipogenesis through TGF-β ligand maintenance, establishing its dual role in cell identity and lineage fate decisions.","evidence":"In vivo metastasis assays showing PRRX1 loss enables colonization with MET and stem cell property acquisition; stable knockdown/overexpression with adipogenesis assays and TGF-β inhibitor rescue","pmids":["23201163","23250756"],"confidence":"High","gaps":["Chromatin-level mechanism of EMT gene regulation by PRRX1 not defined","Whether TGF-β2/3 promoters are direct PRRX1 targets not shown by ChIP"]},{"year":2013,"claim":"Demonstrating isoform-specific functions—PRRX1b binding the Sox9 promoter to regulate acinar-ductal metaplasia while PRRX1a and PRRX1b differentially control migration vs. invasion—revealed that alternative C-termini direct distinct transcriptional programs.","evidence":"Isoform-specific overexpression, Sox9 promoter binding assays, Prrx1creERT2-IRES-GFP lineage tracing in pancreas","pmids":["23355395"],"confidence":"High","gaps":["Structural basis for isoform-specific DNA target selectivity unknown","Genome-wide isoform-specific binding profiles not generated"]},{"year":2017,"claim":"Linking PRRX1 to atrial electrophysiology—showing that PRRX1 suppression shortens atrial action potential duration and that a common SNP in a PRRX1 enhancer alters its expression—connected this developmental transcription factor to atrial fibrillation susceptibility.","evidence":"hESC-derived cardiomyocyte and zebrafish knockdown with electrophysiological recordings; enhancer reporter assays validating rs577676 function","pmids":["28974514"],"confidence":"High","gaps":["Direct cardiac transcriptional targets of PRRX1 mediating action potential regulation not identified at this stage"]},{"year":2019,"claim":"Identifying FOXM1 as a direct physical partner of PRRX1 (through Co-IP and domain mapping) demonstrated that PRRX1 cooperates with non-homeodomain transcription factors beyond SRF to regulate target gene programs including DNA damage response.","evidence":"Reciprocal Co-IP with domain deletion mapping (PRRX1 aa 200–222 to FOXM1 Forkhead domain), luciferase reporters, loss-of-function rescue in pancreatic cancer cells","pmids":["30705403"],"confidence":"High","gaps":["Genome-wide co-occupancy of PRRX1-FOXM1 not mapped","Structural basis of the interaction not resolved"]},{"year":2020,"claim":"Revealing that PRRX1 controls cancer-associated fibroblast plasticity—switching between dormant and activated myofibroblastic states—and that Prrx1-deficient CAFs constitutively secrete HGF to drive tumor subtype switching and chemoresistance established PRRX1 as a stromal fate regulator in the tumor microenvironment.","evidence":"Prrx1 genetic depletion in PDAC mouse model, CAF-tumor organoid co-culture, gene expression subtype analysis","pmids":["33007300"],"confidence":"High","gaps":["Direct transcriptional targets mediating CAF state switching not fully catalogued","Whether PRRX1 regulates HGF promoter directly not determined"]},{"year":2021,"claim":"Multiple studies converged on PRRX1 as a direct promoter-binding activator of TGF-β1 (in glioma), a DNMT3A-recruiting epigenetic silencer of PROM1 (isoform-specific, PRRX1b only), and an upstream controller of MET via the PITX2/miR-200 axis, broadening the repertoire of PRRX1 effector mechanisms beyond simple transcriptional activation.","evidence":"ChIP for TGF-β1 promoter binding with TGF-β1 silencing rescue; Co-IP of PRRX1b-DNMT3A with bisulfite sequencing of PROM1 promoter; epistasis experiments in HCC dissecting PRRX1→PITX2→miR-200→E-cadherin pathway","pmids":["34131109","34214250","33587761"],"confidence":"High","gaps":["Whether DNMT3A recruitment is genome-wide or locus-specific unknown","PRRX1b structural determinants for DNMT3A selectivity not mapped"]},{"year":2021,"claim":"Identification of PRRX1 loss-of-function mutations (p.Gln107* and p.Arg146Ile) as causes of familial atrial fibrillation, with diminished transactivation of ISL1 and SHOX2, established PRRX1 haploinsufficiency as a Mendelian arrhythmia mechanism.","evidence":"Whole-exome sequencing in AF families, Sanger confirmation, luciferase reporter assays showing reduced transactivation and promoter binding of mutant PRRX1","pmids":["34845933"],"confidence":"Medium","gaps":["Independent replication in additional families needed","In vivo electrophysiological validation of these specific mutations not performed","Whether ISL1/SHOX2 are direct or indirect targets not resolved by ChIP"]},{"year":2022,"claim":"Genome-wide super-enhancer profiling established PRRX1 as a master transcription factor that remodels the super-enhancer landscape to convert fibroblasts to myofibroblasts via TGF-β signaling, and fibroblast-specific Prrx1 depletion induced sustained remission of chemotherapy-resistant tumors, demonstrating stromal PRRX1 as a therapeutic vulnerability.","evidence":"ChIP-seq for super-enhancer marks, fibroblast-specific genetic depletion in genetically engineered mouse models of PDAC","pmids":["35589735"],"confidence":"High","gaps":["Which specific super-enhancers are essential for myofibroblast conversion not individually validated","Pharmacological targeting strategy not established"]},{"year":2022,"claim":"Lineage tracing identified Prrx1-expressing cells as rare adult mesenchymal stem cells for bone, adipose, and dermis, and as a pro-fibrotic fibroblast subpopulation in wound repair, resolving their in vivo identity and tissue-regenerative functions.","evidence":"Knock-in Cre/CreERT2 lineage tracing, cell depletion, transplantation assays, single-cell RNA-seq in dermal wound models and homeostatic tissues","pmids":["36456880","33176144"],"confidence":"High","gaps":["Transcriptional targets maintaining stemness vs. driving fibrosis in Prrx1+ cells not distinguished","Human in vivo equivalence of Prrx1+ stem cell population not demonstrated"]},{"year":2023,"claim":"Demonstrating that homeodomain missense variants cause aberrant PRRX1 nuclear localization linked homeodomain integrity to nuclear import as a pathogenic mechanism in craniosynostosis.","evidence":"Immunofluorescence of wild-type vs. mutant PRRX1 in patient-derived and transfected cells","pmids":["37154149"],"confidence":"Medium","gaps":["Nuclear import machinery interacting with PRRX1 homeodomain not identified","Rescue experiments restoring nuclear localization not performed"]},{"year":2024,"claim":"ChIP-validated direct binding of PRRX1 to multiple new promoter targets (TNC, FAP, ANXA6, OLR1) and placement downstream of Twist1 in fibrosis cascades expanded the PRRX1 regulon and solidified its role as a central node in organ fibrosis across kidney, intestine, and heart.","evidence":"ChIP assays for Twist1→Prrx1 promoter and Prrx1→TNC promoter with fibroblast-specific Twist1 KO; ChIP-seq and conditional Prrx1 KO for FAP in intestinal fibrosis; ChIP-PCR for ANXA6 and OLR1 in cancer models","pmids":["39181396","41350883","39528080","39010054"],"confidence":"Medium","gaps":["Comprehensive genome-wide PRRX1 cistrome across tissue contexts not integrated","Co-factor requirements at each target promoter not systematically defined"]},{"year":null,"claim":"The genome-wide binding landscape of endogenous PRRX1 across its major biological contexts (mesenchymal stem cells, fibroblasts, cardiomyocytes, cancer) has not been integrated, and the structural basis for isoform-specific partner selection and target gene discrimination remains unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No crystal or cryo-EM structure of PRRX1 homeodomain with DNA or any partner","Integrated multi-tissue PRRX1 ChIP-seq/CUT&RUN atlas absent","Isoform-specific regulatory mechanisms at the structural level unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[3,7,8,10,15,22,23,25,31,37]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,3,6,7,8,10,13,15,22,23,24,25,28,31,37]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[6,18]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[3,7,36]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[6,10,15,22,27,30]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[7,8,17]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[1,2,5]}],"complexes":[],"partners":["SRF","FOXM1","DNMT3A","SOX2","TOP2A","HDAC1","CBP"],"other_free_text":[]},"mechanistic_narrative":"PRRX1 is a paired-related homeodomain transcription factor that serves as a master regulator of mesenchymal cell identity, controlling epithelial-mesenchymal transition (EMT), fibroblast activation, and mesenchymal stem cell fate across bone, adipose, and dermal lineages. PRRX1 directly binds promoters of diverse target genes—including TGF-β1, Sox9, Osx, FAP, MMP13, IL-6, ABCC1, FKBP5, TNC, COL6A3, OLR1, and ANXA6—to activate or repress transcription, and physically interacts with co-regulators such as SRF, FOXM1, TOP2A, DNMT3A, and SOX2 to shape context-dependent transcriptional outputs [PMID:9343429, PMID:30705403, PMID:34214250, PMID:35589735, PMID:38448751]. Through its two isoforms (PRRX1a and PRRX1b), it differentially regulates migration versus invasion, suppresses adipogenesis via sustained TGF-β ligand expression, drives fibroblast-to-myofibroblast conversion through super-enhancer remodeling, and controls cancer-associated fibroblast plasticity that influences chemoresistance [PMID:23201163, PMID:23250756, PMID:23355395, PMID:33007300, PMID:35589735]. Loss-of-function mutations in the PRRX1 homeodomain cause familial atrial fibrillation through impaired transactivation of cardiac target genes ISL1 and SHOX2, and homeodomain missense variants cause craniosynostosis through defective nuclear localization [PMID:34845933, PMID:37154149]."},"prefetch_data":{"uniprot":{"accession":"P54821","full_name":"Paired mesoderm homeobox protein 1","aliases":["Homeobox protein PHOX1","Paired-related homeobox protein 1","PRX-1"],"length_aa":245,"mass_kda":27.3,"function":"Master transcription factor of stromal fibroblasts for myofibroblastic lineage progression. Orchestrates the functional drift of fibroblasts into myofibroblastic phenotype via TGF-beta signaling by remodeling a super-enhancer landscape. Through this function, plays an essential role in wound healing process (PubMed:35589735). Acts as a transcriptional regulator of muscle creatine kinase (MCK) and so has a role in the establishment of diverse mesodermal muscle types. The protein binds to an A/T-rich element in the muscle creatine enhancer (By similarity). May play a role in homeostasis and regeneration of bone, white adipose tissue and derm (By similarity) Transcriptional activator, when transfected in fibroblastic or myoblastic cell lines. This activity may be masked by the C-terminal OAR domain Transcriptional repressor, when transfected in fibroblastic or myoblastic cell lines","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/P54821/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PRRX1","classification":"Not Classified","n_dependent_lines":3,"n_total_lines":1208,"dependency_fraction":0.0024834437086092716},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PRRX1","total_profiled":1310},"omim":[{"mim_id":"615342","title":"PULMONARY HYPERTENSION, PRIMARY, 2; PPH2","url":"https://www.omim.org/entry/615342"},{"mim_id":"610125","title":"MICROPHTHALMIA, SYNDROMIC 5; MCOPS5","url":"https://www.omim.org/entry/610125"},{"mim_id":"604675","title":"PAIRED-RELATED HOMEOBOX GENE 2; PRRX2","url":"https://www.omim.org/entry/604675"},{"mim_id":"604238","title":"SNAIL FAMILY TRANSCRIPTIONAL REPRESSOR 1; SNAI1","url":"https://www.omim.org/entry/604238"},{"mim_id":"603295","title":"SMAD FAMILY MEMBER 9; SMAD9","url":"https://www.omim.org/entry/603295"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/PRRX1"},"hgnc":{"alias_symbol":["PHOX1"],"prev_symbol":["PMX1"]},"alphafold":{"accession":"P54821","domains":[{"cath_id":"1.10.10.60","chopping":"101-169","consensus_level":"medium","plddt":90.4248,"start":101,"end":169}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P54821","model_url":"https://alphafold.ebi.ac.uk/files/AF-P54821-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P54821-F1-predicted_aligned_error_v6.png","plddt_mean":64.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PRRX1","jax_strain_url":"https://www.jax.org/strain/search?query=PRRX1"},"sequence":{"accession":"P54821","fasta_url":"https://rest.uniprot.org/uniprotkb/P54821.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P54821/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P54821"}},"corpus_meta":[{"pmid":"23201163","id":"PMC_23201163","title":"Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1.","date":"2012","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/23201163","citation_count":794,"is_preprint":false},{"pmid":"10397741","id":"PMC_10397741","title":"NUP98 is fused to PMX1 homeobox gene in human acute myelogenous leukemia with chromosome translocation t(1;11)(q23;p15).","date":"1999","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/10397741","citation_count":108,"is_preprint":false},{"pmid":"24705396","id":"PMC_24705396","title":"MiR-124 Radiosensitizes human colorectal cancer cells by targeting PRRX1.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24705396","citation_count":102,"is_preprint":false},{"pmid":"23355395","id":"PMC_23355395","title":"The Prrx1 homeodomain transcription factor plays a central role in pancreatic regeneration and carcinogenesis.","date":"2013","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/23355395","citation_count":97,"is_preprint":false},{"pmid":"24946010","id":"PMC_24946010","title":"The roles of the epithelial-mesenchymal transition marker PRRX1 and miR-146b-5p in papillary thyroid carcinoma progression.","date":"2014","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24946010","citation_count":90,"is_preprint":false},{"pmid":"25428393","id":"PMC_25428393","title":"PRRX1 promotes epithelial-mesenchymal transition through the Wnt/β-catenin pathway in gastric cancer.","date":"2014","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/25428393","citation_count":84,"is_preprint":false},{"pmid":"35589735","id":"PMC_35589735","title":"PRRX1 is a master transcription factor of stromal fibroblasts for myofibroblastic lineage progression.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35589735","citation_count":82,"is_preprint":false},{"pmid":"33176144","id":"PMC_33176144","title":"Prrx1 Fibroblasts Represent a Pro-fibrotic Lineage in the Mouse Ventral Dermis.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/33176144","citation_count":70,"is_preprint":false},{"pmid":"21539833","id":"PMC_21539833","title":"Blastema induction in aneurogenic state and Prrx-1 regulation by MMPs and FGFs in Ambystoma mexicanum limb regeneration.","date":"2011","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/21539833","citation_count":68,"is_preprint":false},{"pmid":"33007300","id":"PMC_33007300","title":"Mesenchymal Plasticity Regulated by Prrx1 Drives Aggressive Pancreatic Cancer Biology.","date":"2020","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/33007300","citation_count":66,"is_preprint":false},{"pmid":"16651408","id":"PMC_16651408","title":"Trans-repressive effect of NUP98-PMX1 on PMX1-regulated c-FOS gene through recruitment of histone deacetylase 1 by FG repeats.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16651408","citation_count":60,"is_preprint":false},{"pmid":"26820102","id":"PMC_26820102","title":"miR-655 suppresses epithelial-to-mesenchymal transition by targeting Prrx1 in triple-negative breast cancer.","date":"2016","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26820102","citation_count":60,"is_preprint":false},{"pmid":"23250756","id":"PMC_23250756","title":"The transcription factor paired-related homeobox 1 (Prrx1) inhibits adipogenesis by activating transforming growth factor-β (TGFβ) signaling.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23250756","citation_count":57,"is_preprint":false},{"pmid":"36456880","id":"PMC_36456880","title":"Prrx1 marks stem cells for bone, white adipose tissue and dermis in adult mice.","date":"2022","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36456880","citation_count":54,"is_preprint":false},{"pmid":"28033430","id":"PMC_28033430","title":"LGR5 Is a Gastric Cancer Stem Cell Marker Associated with Stemness and the EMT Signature Genes NANOG, NANOGP8, PRRX1, TWIST1, and BMI1.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28033430","citation_count":50,"is_preprint":false},{"pmid":"34131109","id":"PMC_34131109","title":"Prrx1 promotes stemness and angiogenesis via activating TGF-β/smad pathway and upregulating proangiogenic factors in glioma.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/34131109","citation_count":49,"is_preprint":false},{"pmid":"20683885","id":"PMC_20683885","title":"Identification of the homeobox protein Prx1 (MHox, Prrx-1) as a regulator of osterix expression and mediator of tumor necrosis factor α action in osteoblast differentiation.","date":"2011","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/20683885","citation_count":49,"is_preprint":false},{"pmid":"34373601","id":"PMC_34373601","title":"Induction and expansion of human PRRX1+ limb-bud-like mesenchymal cells from pluripotent stem cells.","date":"2021","source":"Nature biomedical engineering","url":"https://pubmed.ncbi.nlm.nih.gov/34373601","citation_count":45,"is_preprint":false},{"pmid":"24770895","id":"PMC_24770895","title":"PRRX1 and PRRX2 distinctively participate in pituitary organogenesis and a cell-supply system.","date":"2014","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/24770895","citation_count":44,"is_preprint":false},{"pmid":"11063257","id":"PMC_11063257","title":"Human PRRX1 and PRRX2 genes: cloning, expression, genomic localization, and exclusion as disease genes for Nager syndrome.","date":"2000","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/11063257","citation_count":42,"is_preprint":false},{"pmid":"30622052","id":"PMC_30622052","title":"PRRX1 Regulates Cellular Phenotype Plasticity and Dormancy of Head and Neck Squamous Cell Carcinoma Through miR-642b-3p.","date":"2019","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/30622052","citation_count":40,"is_preprint":false},{"pmid":"25795141","id":"PMC_25795141","title":"PRRX1- and PRRX2-positive mesenchymal stem/progenitor cells are involved in vasculogenesis during rat embryonic pituitary development.","date":"2015","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/25795141","citation_count":35,"is_preprint":false},{"pmid":"30705403","id":"PMC_30705403","title":"PRRX1 isoforms cooperate with FOXM1 to regulate the DNA damage response in pancreatic cancer cells.","date":"2019","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/30705403","citation_count":34,"is_preprint":false},{"pmid":"30564268","id":"PMC_30564268","title":"gga-mir-133a-3p Regulates Myoblasts Proliferation and Differentiation by Targeting PRRX1.","date":"2018","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30564268","citation_count":34,"is_preprint":false},{"pmid":"28974514","id":"PMC_28974514","title":"Diminished PRRX1 Expression Is Associated With Increased Risk of Atrial Fibrillation and Shortening of the Cardiac Action Potential.","date":"2017","source":"Circulation. Cardiovascular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28974514","citation_count":33,"is_preprint":false},{"pmid":"34608266","id":"PMC_34608266","title":"RNA binding protein RBMS3 is a common EMT effector that modulates triple-negative breast cancer progression via stabilizing PRRX1 mRNA.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/34608266","citation_count":31,"is_preprint":false},{"pmid":"31752959","id":"PMC_31752959","title":"Pre-metastatic niche triggers SDF-1/CXCR4 axis and promotes organ colonisation by hepatocellular circulating tumour cells via downregulation of Prrx1.","date":"2019","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/31752959","citation_count":30,"is_preprint":false},{"pmid":"9174170","id":"PMC_9174170","title":"A competitive mechanism of CArG element regulation by YY1 and SRF: implications for assessment of Phox1/MHox transcription factor interactions at CArG elements.","date":"1997","source":"DNA and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/9174170","citation_count":28,"is_preprint":false},{"pmid":"26617763","id":"PMC_26617763","title":"Down-regualtion of miR-106b induces epithelial-mesenchymal transition but suppresses metastatic colonization by targeting Prrx1 in colorectal cancer.","date":"2015","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26617763","citation_count":28,"is_preprint":false},{"pmid":"31278164","id":"PMC_31278164","title":"The Prrx1 limb enhancer marks an adult subpopulation of injury-responsive dermal fibroblasts.","date":"2019","source":"Biology open","url":"https://pubmed.ncbi.nlm.nih.gov/31278164","citation_count":27,"is_preprint":false},{"pmid":"35475783","id":"PMC_35475783","title":"Mechanical stimulation promotes enthesis injury repair by mobilizing Prrx1+ cells via ciliary TGF-β signaling.","date":"2022","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/35475783","citation_count":26,"is_preprint":false},{"pmid":"33214660","id":"PMC_33214660","title":"COL6A3 expression in adipose tissue cells is associated with levels of the homeobox transcription factor PRRX1.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33214660","citation_count":26,"is_preprint":false},{"pmid":"23444262","id":"PMC_23444262","title":"Recurrent agnathia-otocephaly caused by DNA replication slippage in PRRX1.","date":"2013","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/23444262","citation_count":26,"is_preprint":false},{"pmid":"31657086","id":"PMC_31657086","title":"PRRX1-induced epithelial-to-mesenchymal transition in salivary adenoid cystic carcinoma activates the metabolic reprogramming of free fatty acids to promote invasion and metastasis.","date":"2019","source":"Cell proliferation","url":"https://pubmed.ncbi.nlm.nih.gov/31657086","citation_count":23,"is_preprint":false},{"pmid":"32368097","id":"PMC_32368097","title":"Effects of miR-330-3p on Invasion, Migration and EMT of Gastric Cancer Cells by Targeting PRRX1-Mediated Wnt/β-Catenin Signaling Pathway.","date":"2020","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32368097","citation_count":22,"is_preprint":false},{"pmid":"9343429","id":"PMC_9343429","title":"Protein and DNA contact surfaces that mediate the selective action of the Phox1 homeodomain at the c-fos serum response element.","date":"1997","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9343429","citation_count":21,"is_preprint":false},{"pmid":"22198066","id":"PMC_22198066","title":"Agnathia-otocephaly complex: a case report and examination of the OTX2 and PRRX1 genes.","date":"2011","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/22198066","citation_count":19,"is_preprint":false},{"pmid":"34272753","id":"PMC_34272753","title":"PRRX1-NCOA1-rearranged fibroblastic tumour: a clinicopathological, immunohistochemical and molecular genetic study of six cases of a potentially under-recognised, distinctive mesenchymal tumour.","date":"2021","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/34272753","citation_count":19,"is_preprint":false},{"pmid":"18604245","id":"PMC_18604245","title":"Leukemogenic properties of NUP98-PMX1 are linked to NUP98 and homeodomain sequence functions but not to binding properties of PMX1 to serum response factor.","date":"2008","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/18604245","citation_count":17,"is_preprint":false},{"pmid":"32820613","id":"PMC_32820613","title":"Fatty acid synthase contributes to epithelial-mesenchymal transition and invasion of salivary adenoid cystic carcinoma through PRRX1/Wnt/β-catenin pathway.","date":"2020","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32820613","citation_count":16,"is_preprint":false},{"pmid":"34295164","id":"PMC_34295164","title":"The Regulatory Role of PRRX1 in Cancer Epithelial-Mesenchymal Transition.","date":"2021","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/34295164","citation_count":15,"is_preprint":false},{"pmid":"37338620","id":"PMC_37338620","title":"\"PRRX1-rearranged mesenchymal tumors\": expanding the immunohistochemical profile and molecular spectrum of a recently described entity with the proposed revision of nomenclature.","date":"2023","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/37338620","citation_count":15,"is_preprint":false},{"pmid":"31667455","id":"PMC_31667455","title":"Site-Specific Load-Induced Expansion of Sca-1+Prrx1+ and Sca-1-Prrx1+ Cells in Adult Mouse Long Bone Is Attenuated With Age.","date":"2019","source":"JBMR plus","url":"https://pubmed.ncbi.nlm.nih.gov/31667455","citation_count":15,"is_preprint":false},{"pmid":"32676335","id":"PMC_32676335","title":"PRRX1 isoform PRRX1A regulates the stemness phenotype and epithelial-mesenchymal transition (EMT) of cancer stem-like cells (CSCs) derived from non-small cell lung cancer (NSCLC).","date":"2020","source":"Translational lung cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/32676335","citation_count":15,"is_preprint":false},{"pmid":"39181396","id":"PMC_39181396","title":"Transcription factor Twist1 drives fibroblast activation to promote kidney fibrosis via signaling proteins Prrx1/TNC.","date":"2024","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/39181396","citation_count":14,"is_preprint":false},{"pmid":"36119823","id":"PMC_36119823","title":"Prrx1 promotes resistance to temozolomide by upregulating ABCC1 and inducing vasculogenic mimicry in glioma.","date":"2022","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/36119823","citation_count":13,"is_preprint":false},{"pmid":"34845933","id":"PMC_34845933","title":"PRRX1 Loss-of-Function Mutations Underlying Familial Atrial Fibrillation.","date":"2021","source":"Journal of the American Heart Association","url":"https://pubmed.ncbi.nlm.nih.gov/34845933","citation_count":13,"is_preprint":false},{"pmid":"33587761","id":"PMC_33587761","title":"PRRX1 deficiency induces mesenchymal-epithelial transition through PITX2/miR-200-dependent SLUG/CTNNB1 regulation in hepatocellular carcinoma.","date":"2021","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/33587761","citation_count":13,"is_preprint":false},{"pmid":"34647172","id":"PMC_34647172","title":"The emerging PRRX1-NCOA fibroblastic neoplasm: a combined reappraisal of published tumors and two new cases.","date":"2021","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/34647172","citation_count":12,"is_preprint":false},{"pmid":"37387366","id":"PMC_37387366","title":"PRRX1+MSCs Enhance Mandibular Regeneration during Distraction Osteogenesis.","date":"2023","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/37387366","citation_count":12,"is_preprint":false},{"pmid":"33395745","id":"PMC_33395745","title":"PRRX1 promotes malignant properties in human osteosarcoma.","date":"2020","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33395745","citation_count":12,"is_preprint":false},{"pmid":"33530259","id":"PMC_33530259","title":"Low PRRX1 expression and high ZEB1 expression are significantly correlated with epithelial-mesenchymal transition and tumor angiogenesis in non-small cell lung cancer.","date":"2021","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33530259","citation_count":12,"is_preprint":false},{"pmid":"32811812","id":"PMC_32811812","title":"The rs7911488-T allele promotes the growth and metastasis of colorectal cancer through modulating miR-1307/PRRX1.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32811812","citation_count":11,"is_preprint":false},{"pmid":"33970764","id":"PMC_33970764","title":"Activation of COL11A1 by PRRX1 promotes tumor progression and radioresistance in ovarian cancer.","date":"2021","source":"International journal of radiation biology","url":"https://pubmed.ncbi.nlm.nih.gov/33970764","citation_count":11,"is_preprint":false},{"pmid":"35377386","id":"PMC_35377386","title":"A novel PRRX1 loss-of-function variation contributing to familial atrial fibrillation and congenital patent ductus arteriosus.","date":"2022","source":"Genetics and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/35377386","citation_count":11,"is_preprint":false},{"pmid":"34092116","id":"PMC_34092116","title":"A Variant Noncoding Region Regulates Prrx1 and Predisposes to Atrial Arrhythmias.","date":"2021","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/34092116","citation_count":11,"is_preprint":false},{"pmid":"33561660","id":"PMC_33561660","title":"Isolation of PRRX1-positive adult pituitary stem/progenitor cells from the marginal cell layer of the mouse anterior lobe.","date":"2021","source":"Stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/33561660","citation_count":11,"is_preprint":false},{"pmid":"36273425","id":"PMC_36273425","title":"The paired-related homeobox protein 1 promotes cardiac fibrosis via the Twist1-Prrx1-tenascin-C loop.","date":"2022","source":"Cell biology international","url":"https://pubmed.ncbi.nlm.nih.gov/36273425","citation_count":10,"is_preprint":false},{"pmid":"28469771","id":"PMC_28469771","title":"Loss of PRRX1 induces epithelial-mesenchymal transition and cancer stem cell-like properties in A549 cells.","date":"2017","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/28469771","citation_count":10,"is_preprint":false},{"pmid":"28337269","id":"PMC_28337269","title":"The role of PRRX1 in the apoptosis of A549 cells induced by cisplatin.","date":"2017","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/28337269","citation_count":10,"is_preprint":false},{"pmid":"33578599","id":"PMC_33578599","title":"PRRX1 promotes lymph node metastasis of gastric cancer by regulating epithelial-mesenchymal transition.","date":"2021","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33578599","citation_count":10,"is_preprint":false},{"pmid":"35583270","id":"PMC_35583270","title":"Pigmented PRRX1::NCOA1-rearranged fibroblastic tumor: A rare morphologic variant of an emerging mesenchymal tumor.","date":"2022","source":"Journal of cutaneous pathology","url":"https://pubmed.ncbi.nlm.nih.gov/35583270","citation_count":10,"is_preprint":false},{"pmid":"39010054","id":"PMC_39010054","title":"PRRX1-OLR1 axis supports CAFs-mediated lung cancer progression and immune suppression.","date":"2024","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/39010054","citation_count":9,"is_preprint":false},{"pmid":"27578582","id":"PMC_27578582","title":"[miR-124 regulates radiosensitivity of colorectal cancer cells by targeting PRRX1].","date":"2016","source":"Nan fang yi ke da xue xue bao = Journal of Southern Medical University","url":"https://pubmed.ncbi.nlm.nih.gov/27578582","citation_count":9,"is_preprint":false},{"pmid":"31490389","id":"PMC_31490389","title":"Aberrant expression of vasculogenic mimicry, PRRX1, and CIP2A in clear cell renal cell carcinoma and its clinicopathological significance.","date":"2019","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31490389","citation_count":9,"is_preprint":false},{"pmid":"34967278","id":"PMC_34967278","title":"Transcription factor paired related homeobox 1 (PRRX1) activates matrix metalloproteinases (MMP)13, which promotes the dextran sulfate sodium-induced inflammation and barrier dysfunction of NCM460 cells.","date":"2022","source":"Bioengineered","url":"https://pubmed.ncbi.nlm.nih.gov/34967278","citation_count":8,"is_preprint":false},{"pmid":"36636075","id":"PMC_36636075","title":"PRRX1 promotes colorectal cancer stemness and chemoresistance via the JAK2/STAT3 axis by targeting IL-6.","date":"2022","source":"Journal of gastrointestinal oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36636075","citation_count":7,"is_preprint":false},{"pmid":"37154149","id":"PMC_37154149","title":"Pathogenic variants in the paired-related homeobox 1 gene (PRRX1) cause craniosynostosis with incomplete penetrance.","date":"2023","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37154149","citation_count":7,"is_preprint":false},{"pmid":"34214250","id":"PMC_34214250","title":"PRRX1 induced by BMP signaling decreases tumorigenesis by epigenetically regulating glioma-initiating cell properties via DNA methyltransferase 3A.","date":"2021","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34214250","citation_count":7,"is_preprint":false},{"pmid":"31545082","id":"PMC_31545082","title":"Transcription Factor prrx1 Promotes Brown Adipose-Derived Stem Cells Differentiation to Sinus Node-Like Cells.","date":"2019","source":"DNA and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/31545082","citation_count":7,"is_preprint":false},{"pmid":"35462225","id":"PMC_35462225","title":"SPOCK1 silencing decreases 5-FU resistance through PRRX1 in colorectal cancer.","date":"2022","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/35462225","citation_count":6,"is_preprint":false},{"pmid":"40044064","id":"PMC_40044064","title":"Cardioprotective potential of transcription factor PRRX1 silencing against myocardial ischemia/reperfusion injury by regulating excessive mitophagy and ferroptosis through FKBP5-p38 MAPK axis.","date":"2025","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/40044064","citation_count":6,"is_preprint":false},{"pmid":"34286520","id":"PMC_34286520","title":"LncRNA FEZF1-AS1 promotes colorectal cancer progression through regulating the miR-363-3p/PRRX1 pathway.","date":"2021","source":"Advances in clinical and experimental medicine : official organ Wroclaw Medical University","url":"https://pubmed.ncbi.nlm.nih.gov/34286520","citation_count":6,"is_preprint":false},{"pmid":"32862590","id":"PMC_32862590","title":"Relationship between PRRX1, circulating tumor cells, and clinicopathological parameter in patients with gastric cancer.","date":"2020","source":"Journal of B.U.ON. : official journal of the Balkan Union of Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32862590","citation_count":6,"is_preprint":false},{"pmid":"33620119","id":"PMC_33620119","title":"Tumor suppressive microRNA-485-5p targets PRRX1 in human skin melanoma cells, regulating epithelial-mesenchymal transition and apoptosis.","date":"2021","source":"Cell biology international","url":"https://pubmed.ncbi.nlm.nih.gov/33620119","citation_count":6,"is_preprint":false},{"pmid":"38154915","id":"PMC_38154915","title":"Revealing RB1 loss in an emerging entity: report of two cases of PRRX1-rearranged mesenchymal tumours.","date":"2025","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/38154915","citation_count":6,"is_preprint":false},{"pmid":"38448751","id":"PMC_38448751","title":"PRRX1-TOP2A interaction is a malignancy-promoting factor in human malignant peripheral nerve sheath tumours.","date":"2024","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/38448751","citation_count":6,"is_preprint":false},{"pmid":"34738916","id":"PMC_34738916","title":"Downregulation of miR-216a-5p and miR-652-3p is associated with growth and invasion by targeting JAK2 and PRRX1 in GH-producing pituitary tumours.","date":"2021","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/34738916","citation_count":6,"is_preprint":false},{"pmid":"31938377","id":"PMC_31938377","title":"PRRX1 drives tamoxifen therapy resistance through induction of epithelial-mesenchymal transition in MCF-7 breast cancer cells.","date":"2018","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31938377","citation_count":6,"is_preprint":false},{"pmid":"38986510","id":"PMC_38986510","title":"PRRX1-fused mesenchymal neoplasm: A novel PRRX1::NCOA1 fusion transcript.","date":"2024","source":"Journal of cutaneous pathology","url":"https://pubmed.ncbi.nlm.nih.gov/38986510","citation_count":5,"is_preprint":false},{"pmid":"15182531","id":"PMC_15182531","title":"[Development of human myeloid leukemia-like phenotype in NUP98-PMX1 transgenic mice].","date":"2004","source":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","url":"https://pubmed.ncbi.nlm.nih.gov/15182531","citation_count":5,"is_preprint":false},{"pmid":"32417536","id":"PMC_32417536","title":"Deletion of α-Synuclein in Prrx1-positive cells causes partial loss of function in the central nervous system (CNS) but does not affect ovariectomy induced bone loss.","date":"2020","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/32417536","citation_count":5,"is_preprint":false},{"pmid":"36092834","id":"PMC_36092834","title":"PRRX1/FOXM1 reduces gemcitabin-induced cytotoxicity by regulating autophagy in bladder cancer.","date":"2022","source":"Translational andrology and urology","url":"https://pubmed.ncbi.nlm.nih.gov/36092834","citation_count":5,"is_preprint":false},{"pmid":"36959186","id":"PMC_36959186","title":"ABL1 kinase as a tumor suppressor in AML1-ETO and NUP98-PMX1 leukemias.","date":"2023","source":"Blood cancer journal","url":"https://pubmed.ncbi.nlm.nih.gov/36959186","citation_count":4,"is_preprint":false},{"pmid":"35137272","id":"PMC_35137272","title":"Age-Progressive and Gender-Dependent Bone Phenotype in Mice Lacking Both Ebf1 and Ebf2 in Prrx1-Expressing Mesenchymal Cells.","date":"2022","source":"Calcified tissue international","url":"https://pubmed.ncbi.nlm.nih.gov/35137272","citation_count":4,"is_preprint":false},{"pmid":"32146343","id":"PMC_32146343","title":"Nicotine inhibits expression of Prrx1 in pituitary stem/progenitor cells through epigenetic regulation, leading to a delayed supply of growth-hormone-producing cells.","date":"2020","source":"Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/32146343","citation_count":4,"is_preprint":false},{"pmid":"36968142","id":"PMC_36968142","title":"A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases.","date":"2023","source":"Cancer research communications","url":"https://pubmed.ncbi.nlm.nih.gov/36968142","citation_count":3,"is_preprint":false},{"pmid":"39528080","id":"PMC_39528080","title":"Transcription factor PRRX1-activated ANXA6 facilitates EGFR-PKCα complex formation and enhances cisplatin sensitivity in bladder cancer.","date":"2024","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39528080","citation_count":3,"is_preprint":false},{"pmid":"38869718","id":"PMC_38869718","title":"LncRNA KIFAP3-5:1 inhibits epithelial-mesenchymal transition of renal tubular cell through PRRX1 in diabetic nephropathy.","date":"2024","source":"Cell biology and toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/38869718","citation_count":3,"is_preprint":false},{"pmid":"38643083","id":"PMC_38643083","title":"Reciprocal negative feedback between Prrx1 and miR-140-3p regulates rapid chondrogenesis in the regenerating antler.","date":"2024","source":"Cellular & molecular biology letters","url":"https://pubmed.ncbi.nlm.nih.gov/38643083","citation_count":3,"is_preprint":false},{"pmid":"35269809","id":"PMC_35269809","title":"Identification of Surface Antigens That Define Human Pluripotent Stem Cell-Derived PRRX1+Limb-Bud-like Mesenchymal Cells.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35269809","citation_count":3,"is_preprint":false},{"pmid":"27580127","id":"PMC_27580127","title":"Clinicopathologic Correlations of E-cadherin and Prrx-1 Expression Loss in Hepatocellular Carcinoma.","date":"2016","source":"Journal of pathology and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27580127","citation_count":3,"is_preprint":false},{"pmid":"39887195","id":"PMC_39887195","title":"PRRX1-Rearranged Mesenchymal Tumor in a Core Needle Biopsy.","date":"2025","source":"International journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/39887195","citation_count":3,"is_preprint":false},{"pmid":"34001105","id":"PMC_34001105","title":"First case report of a NUP98-PMX1 rearrangement in de novo acute myeloid leukemia and literature review.","date":"2021","source":"BMC medical genomics","url":"https://pubmed.ncbi.nlm.nih.gov/34001105","citation_count":2,"is_preprint":false},{"pmid":"40860778","id":"PMC_40860778","title":"Extracellular Matrix Stiffness Enhancement Promotes Docetaxel Resistance in Prostate Cancer via Inhibition of Apoptosis Mediated by Upregulation of PRRX1.","date":"2025","source":"International journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40860778","citation_count":2,"is_preprint":false},{"pmid":"37790521","id":"PMC_37790521","title":"Prrx1-driven LINC complex disruption in vivo reduces osteoid deposition but not bone quality after voluntary wheel running.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/37790521","citation_count":2,"is_preprint":false},{"pmid":"41350883","id":"PMC_41350883","title":"PEGylated black-phosphorus nanosheet-alginate hydrogels enable local PRRX1 delivery to drive fibroblast reprogramming in intestinal fibrosis.","date":"2025","source":"Journal of nanobiotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/41350883","citation_count":1,"is_preprint":false},{"pmid":"38638845","id":"PMC_38638845","title":"Identification and validation of PCDHGA12 and PRRX1 methylation for detecting lung cancer in bronchial washing sample.","date":"2024","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/38638845","citation_count":1,"is_preprint":false},{"pmid":"41230906","id":"PMC_41230906","title":"PRRX1 Orchestrates Pericyte-Myofibroblast Transition in Pathological Retinal Fibrosis.","date":"2025","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/41230906","citation_count":1,"is_preprint":false},{"pmid":"40159029","id":"PMC_40159029","title":"[PRRX1-rearranged fibroblastic tumor: a clinicopathological and molecular analysis of four cases].","date":"2025","source":"Zhonghua bing li xue za zhi = Chinese journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/40159029","citation_count":1,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53443,"output_tokens":8642,"usd":0.14498},"stage2":{"model":"claude-opus-4-6","input_tokens":12584,"output_tokens":4471,"usd":0.262043},"total_usd":0.407023,"stage1_batch_id":"msgbatch_01SUR8NDzVrNmyszWyJeCct7","stage2_batch_id":"msgbatch_01G7Yfutko3cDWzejrwH5AMx","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2012,\n      \"finding\": \"PRRX1 is an EMT inducer that confers migratory and invasive properties on carcinoma cells; loss of PRRX1 is required for metastatic colonization in vivo, with reversion to epithelial phenotype concomitant with acquisition of stem cell properties, demonstrating that PRRX1 uncouples EMT and stemness.\",\n      \"method\": \"In vivo metastasis assays, loss-of-function (knockdown) and gain-of-function in cancer cell lines, EMT marker analysis\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO/KD with defined cellular phenotype in vitro and in vivo, replicated across multiple cancer models\",\n      \"pmids\": [\"23201163\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"In AML with t(1;11)(q23;p15), NUP98 is fused in-frame to PMX1 (PRRX1); the fusion protein retains the PMX1 homeodomain and the N-terminal GLFG-rich NUP98 transcriptional activation domain, suggesting the fusion acts as an oncogenic transcription factor by upregulating PMX1 homeodomain-driven transcription.\",\n      \"method\": \"Molecular cloning, RT-PCR, translocation breakpoint sequencing\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — molecular characterization of fusion transcript, single lab, no functional reconstitution\",\n      \"pmids\": [\"10397741\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The NUP98-PMX1 fusion protein trans-represses PMX1/SRF-mediated c-FOS activation by recruiting histone deacetylase 1 (HDAC1) via its FG repeat domains; the FG domains also bind CBP (a coactivator), giving the fusion dual trans-activator and trans-repressor activity.\",\n      \"method\": \"Luciferase reporter assays, co-immunoprecipitation, protein biochemical assays, molecular cloning\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP and functional reporter assays with multiple orthogonal methods in one study\",\n      \"pmids\": [\"16651408\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Phox1 (PRRX1 human ortholog) activates the c-fos serum response element (SRE) by interacting with serum response factor (SRF); residues on helices 1 and 2 of the homeodomain (not required for DNA binding) mediate contact with an accessory factor, while major-groove DNA contact is also required for SRE activation in vivo.\",\n      \"method\": \"Detailed homeodomain mutagenesis, in vivo transcription assays, domain-swap experiments\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic mutagenesis with functional in vivo validation, rigorous mechanistic dissection\",\n      \"pmids\": [\"9343429\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Phox1/MHox (PRRX1) overexpression does not diminish YY1-mediated repression of CArG elements, indicating that Phox1 transcriptional activation at the SRE does not operate through enhanced SRF binding; YY1 represses CArG elements by competing with SRF for overlapping binding sites.\",\n      \"method\": \"In vitro binding competition assays, serial point mutagenesis of CArG element, in vivo overexpression reporter assays\",\n      \"journal\": \"DNA and cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — in vitro binding and in vivo reporter assays, single lab\",\n      \"pmids\": [\"9174170\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Leukemogenic transformation by NUP98-PMX1 requires the NUP98 GLFG domain and the DNA-binding capability of the PMX1 homeodomain, but is independent of PMX1's ability to interact with SRF; NUP98-PMX1 collaborates with Meis1 to accelerate myeloproliferative leukemia.\",\n      \"method\": \"Strategic homeodomain mutations, retroviral transduction of murine myeloid progenitors, myeloid differentiation and proliferation assays, in vivo leukemia model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — epistasis via strategic mutagenesis and in vivo leukemia model with multiple orthogonal methods\",\n      \"pmids\": [\"18604245\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"PRRX1a and PRRX1b are negative regulators of adipogenesis; they inhibit PPARγ activity and sustain expression of TGFβ2 and TGFβ3, and their knockdown enhances adipogenesis, which is phenocopied by TGFβ signaling inhibition, establishing a PRRX1→TGFβ→adipogenesis suppression axis.\",\n      \"method\": \"Stable knockdown, transient overexpression, adipogenesis assays, PPARγ reporter assays, TGFβ pathway inhibition, in vivo adipose tissue analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (KD, OE, reporter, inhibitor rescue, in vivo), single lab\",\n      \"pmids\": [\"23250756\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"TNF-α stimulates a 14-fold increase in Prx1 (PRRX1) mRNA in preosteoblasts; Prx1 binds the Osterix (Osx) promoter (confirmed by ChIP), and its expression inhibits Osx and RUNX2 transcription; siRNA silencing of Prx1 abrogates TNF-mediated suppression of Osx, identifying Prx1 as an obligate mediator of TNF inhibition of osteoblast differentiation.\",\n      \"method\": \"Protein pull-down from nuclear extracts + mass spectrometry, ChIP assay, siRNA knockdown, transient expression, EMSA\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — ChIP, EMSA, and siRNA rescue with multiple orthogonal methods in one study\",\n      \"pmids\": [\"20683885\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The PRRX1b isoform specifically binds the Sox9 promoter and positively regulates Sox9 expression in pancreatic cells, placing PRRX1b upstream of Sox9 in a hierarchical axis that influences acinar-ductal metaplasia; the two isoforms, PRRX1a and PRRX1b, regulate migration and invasion respectively in pancreatic cancer cells.\",\n      \"method\": \"Isoform-specific overexpression, promoter binding assays, sorted Prrx1+ cell functional assays, lineage tracing (Prrx1creERT2-IRES-GFP mice)\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods including lineage tracing, isoform-specific functional assays, and promoter binding in one study\",\n      \"pmids\": [\"23355395\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PRRX1 directly physically interacts with FOXM1 via the PRRX1A/B 200–222/217 aa region and the FOXM1 Forkhead domain; this interaction mediates cooperative transcriptional regulation of FOXM1-dependent targets and limits induction of DNA damage in pancreatic cancer cells.\",\n      \"method\": \"Co-immunoprecipitation, domain deletion mapping, luciferase reporter assays, loss-of-function and rescue experiments\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP with domain mapping and functional reporter validation, moderate evidence\",\n      \"pmids\": [\"30705403\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PRRX1 directly binds to the promoter region of the TGF-β1 gene, upregulates TGF-β1 expression, and activates the TGF-β/Smad pathway to promote stemness and angiogenesis in glioma; silencing TGF-β1 reverses PRRX1-induced malignant behaviors.\",\n      \"method\": \"Subcellular proteomics, ChIP assay (promoter binding), TGF-β1 silencing rescue experiments, in vivo knockdown\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and rescue experiments, single lab\",\n      \"pmids\": [\"34131109\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Upon BMP stimulation, the PRRX1b (pmx-1b) isoform interacts with DNA methyltransferase DNMT3A and induces promoter methylation of PROM1 (CD133), reducing the CD133-positive glioma-initiating cell population and inhibiting tumorigenicity in vivo; the PRRX1a isoform does not have this activity.\",\n      \"method\": \"Co-immunoprecipitation of PRRX1b-DNMT3A, bisulfite sequencing of PROM1 promoter, DNMT3A silencing rescue, in vivo tumorigenicity assays\",\n      \"journal\": \"Molecular oncology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — Co-IP, bisulfite sequencing, and in vivo rescue with orthogonal methods in one study\",\n      \"pmids\": [\"34214250\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Suppression of PRRX1 in human embryonic stem cell-derived cardiomyocytes and embryonic zebrafish results in shortening of the atrial action potential duration, a hallmark of atrial fibrillation; a functional SNP (rs577676) in a PRRX1 enhancer alters enhancer activity and differentially regulates PRRX1 expression in human left atria.\",\n      \"method\": \"hESC-derived cardiomyocyte loss-of-function, zebrafish embryo knockdown, enhancer reporter assays in mouse atrial cell line, electrophysiological action potential measurement\",\n      \"journal\": \"Circulation. Cardiovascular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal models (hESC-CMs, zebrafish) with defined electrophysiological phenotype and enhancer functional validation\",\n      \"pmids\": [\"28974514\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PRRX1 loss-of-function mutations (p.Gln107* and p.Arg146Ile) cause familial atrial fibrillation; both mutants show significantly diminished transactivation of downstream target genes ISL1 and SHOX2 and markedly decreased ability to bind their promoters, despite normal intracellular distribution.\",\n      \"method\": \"Whole-exome sequencing, Sanger sequencing, luciferase reporter gene assays (transactivation), promoter-binding assays in HeLa cells\",\n      \"journal\": \"Journal of the American Heart Association\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional reporter and binding assays with disease-linked mutations, single lab\",\n      \"pmids\": [\"34845933\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"A variant noncoding region regulates Prrx1 expression and, when altered, predisposes to atrial arrhythmias by changing atrial electrophysiology.\",\n      \"method\": \"Functional validation of noncoding variant, in vivo electrophysiological measurements\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional noncoding variant validation with electrophysiological phenotype\",\n      \"pmids\": [\"34092116\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PRRX1 is a master transcription factor that remodels super-enhancer landscapes to drive fibroblasts toward a myofibroblastic phenotype via TGF-β signaling; fibroblast-specific Prrx1 depletion induces sustained complete remission of chemotherapy-resistant cancer in genetically engineered mouse models.\",\n      \"method\": \"Super-enhancer profiling (ChIP-seq), fibroblast-specific genetic depletion in GEMM, functional in vitro assays, CAF co-culture experiments\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — super-enhancer ChIP-seq, GEMM loss-of-function, multiple orthogonal functional assays\",\n      \"pmids\": [\"35589735\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Prrx1-expressing fibroblasts are a lineage-traced pro-fibrotic subpopulation in mouse ventral dermis responsible for acute and chronic fibroses during wound repair, as demonstrated by lineage tracing and single-cell transcriptomics.\",\n      \"method\": \"Lineage tracing (Prrx1-Cre), single-cell RNA sequencing, fibrosis models\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — lineage tracing plus single-cell transcriptomics with functional wound repair phenotype\",\n      \"pmids\": [\"33176144\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Rare Prrx1-expressing cells act as stem cells for bone, white adipose tissue, and dermis in adult mice; genetic lineage tracing and cell depletion experiments show they are indispensable for tissue homeostasis and repair, and their activity is regulated by Wnt signaling.\",\n      \"method\": \"Knock-in Cre/CreERT2 lineage tracing, cell depletion, single-cell transcriptomics, transplantation assays\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic lineage tracing, transplantation, single-cell profiling with multiple orthogonal methods\",\n      \"pmids\": [\"36456880\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Prrx1 in cancer-associated fibroblasts is critical for tuning CAF activation state, allowing dynamic switching between dormant and activated (myofibroblastic) states; Prrx1-deficient CAFs remain constitutively activated and alter tumor differentiation and gemcitabine resistance through CAF-derived hepatocyte growth factor.\",\n      \"method\": \"Genetic depletion of Prrx1 in PDAC mouse model, primary fibroblast functional assays, tumor organoid-CAF co-culture, gene expression analysis\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic depletion plus co-culture organoid experiments with defined molecular mechanism\",\n      \"pmids\": [\"33007300\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PRRX1 knockdown in HCC promotes mesenchymal-to-epithelial transition (MET) and metastatic colonization; mechanistically, PRRX1 deficiency upregulates PITX2, which increases miR-200a and miR-200b/429, which in turn suppress CTNNB1 and SLUG respectively, enabling E-cadherin re-expression.\",\n      \"method\": \"Knockdown/overexpression in HCC cell lines, microarray, animal metastasis model, pathway epistasis experiments\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epistasis pathway dissection with animal model, single lab\",\n      \"pmids\": [\"33587761\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"RBMS3 RNA-binding protein stabilizes PRRX1 mRNA post-transcriptionally (shown by actinomycin D mRNA stability assays and RBMS3-PRRX1 mRNA interaction), and PRRX1 is required for RBMS3-mediated EMT in triple-negative breast cancer.\",\n      \"method\": \"Genome-wide mRNA stability assay (actinomycin D chase), RNA-binding protein interaction, loss-of-function rescue experiments\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mRNA stability assay and interaction validated with rescue experiments, single lab\",\n      \"pmids\": [\"34608266\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Prrx1 CAF plasticity promotes PDAC tumor squamous subtype and gemcitabine resistance via CAF-derived hepatocyte growth factor (HGF) signaling to tumor cells.\",\n      \"method\": \"CAF-tumor organoid co-culture, gene expression subtype analysis, Prrx1 fibroblast-specific depletion in vivo\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — co-culture mechanistic experiments with in vivo genetic validation, single lab\",\n      \"pmids\": [\"33007300\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Twist1 directly binds to the Prrx1 promoter to drive its expression in kidney fibroblasts; Prrx1 in turn directly binds the TNC (tenascin-C) promoter to promote fibroblast activation and kidney fibrosis, establishing a Twist1→Prrx1→TNC signaling axis.\",\n      \"method\": \"ChIP assay (Twist1 binding to Prrx1 promoter; Prrx1 binding to TNC promoter), fibroblast-specific Twist1 knockout mice, gain- and loss-of-function experiments\",\n      \"journal\": \"Kidney international\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — ChIP demonstrating direct promoter binding at two levels of the cascade, validated with fibroblast-specific KO mouse model\",\n      \"pmids\": [\"39181396\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PRRX1 promotes resistance to temozolomide in glioma by directly binding the ABCC1 promoter and initiating its transcription, upregulating ABCC1 drug transporter expression; PRRX1 also facilitates vasculogenic mimicry formation as an extrinsic resistance mechanism.\",\n      \"method\": \"ChIP assay (PRRX1 binding to ABCC1 promoter), siRNA knockdown, in vitro and in vivo drug sensitivity assays\",\n      \"journal\": \"American journal of cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP confirming direct promoter binding, functional rescue with ABCC1 knockdown, single lab\",\n      \"pmids\": [\"36119823\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PRRX1 directly transactivates the COL6A3 promoter in adipose cells (shown by reporter assay with endogenous COL6A3 promoter), and PRRX1 knockdown reduces COL6A3 mRNA, identifying PRRX1 as a direct transcriptional regulator of COL6A3.\",\n      \"method\": \"Reporter assay (endogenous COL6A3 promoter), siRNA knockdown, stable overexpression in 3T3-L1 cells\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct promoter reporter assay confirmed by KD and OE, single lab\",\n      \"pmids\": [\"33214660\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PRRX1 directly binds the MMP13 promoter (validated by luciferase reporter and ChIP assay) and activates MMP13 transcription, which in turn promotes inflammation and barrier dysfunction in colonic epithelial cells.\",\n      \"method\": \"ChIP assay, luciferase reporter assay, siRNA knockdown, overexpression, ELISA, TEER measurement\",\n      \"journal\": \"Bioengineered\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and reporter assay with functional readouts, single lab\",\n      \"pmids\": [\"34967278\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PRRX1 promotes OLR1 expression in cancer-associated fibroblasts by recruiting active histone marks H3K27ac and H3K4me3 to the OLR1 locus, activating CAFs to support lung cancer growth and immune evasion.\",\n      \"method\": \"ChIP-seq (H3K27ac, H3K4me3), ChIP-qPCR, luciferase reporter assay, PRRX1 and OLR1 knockdown in CAFs, co-culture experiments\",\n      \"journal\": \"Cancer cell international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-seq and functional co-culture validation, single lab\",\n      \"pmids\": [\"39010054\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The Twist1-Prrx1-TNC positive feedback loop drives cardiac fibroblast activation to myofibroblasts; Prrx1 overexpression promotes cardiac fibroblast proliferation, migration, and myofibroblast transformation, while Prrx1 silencing attenuates TGF-β1-induced cardiac fibrosis in vitro.\",\n      \"method\": \"Overexpression and knockdown of Prrx1 in cardiac fibroblasts, TGF-β1 stimulation, proliferation and migration assays\",\n      \"journal\": \"Cell biology international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — functional KD/OE with defined phenotype and pathway placement, single lab\",\n      \"pmids\": [\"36273425\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PRRX1 directly transactivates the IL-6 promoter (confirmed by JASPAR prediction and dual-luciferase reporter assay), and IL-6 activates JAK2/STAT3 signaling to promote colorectal cancer stemness and chemoresistance.\",\n      \"method\": \"Dual-luciferase reporter assay, GSEA, Western blot, in vivo xenograft, ELISA\",\n      \"journal\": \"Journal of gastrointestinal oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reporter assay with in vivo functional validation, single lab\",\n      \"pmids\": [\"36636075\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PRRX1 co-immunoprecipitates with TOP2A in malignant peripheral nerve sheath tumour (MPNST) cells; overexpressed PRRX1 directly interacts with TOP2A to cooperatively promote EMT and expression of tumour malignancy-related gene sets including mTORC1, KRAS, and SRC signaling pathways.\",\n      \"method\": \"Co-immunoprecipitation, mass spectrometry, RNA-seq, structural prediction, PRRX1 knockdown/overexpression\",\n      \"journal\": \"British journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP with mass spectrometry confirmation and transcriptomic validation, single lab\",\n      \"pmids\": [\"38448751\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PRRX1 transcriptionally activates FKBP5 (directly promoting FKBP5 expression) and thereby activates p38 MAPK signaling to drive excessive mitophagy and cardiomyocyte ferroptosis during myocardial ischemia/reperfusion injury; PRRX1 silencing is cardioprotective.\",\n      \"method\": \"siRNA knockdown, FKBP5 overexpression rescue, p38 MAPK inhibitor, in vitro OGD/R model, in vivo rat I/R model\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular basis of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epistasis via rescue and inhibitor experiments with in vivo validation, single lab\",\n      \"pmids\": [\"40044064\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PRRX1 directly transactivates the FAP (fibroblast activation protein) promoter (confirmed by ChIP-seq and reporter assays), establishing a PRRX1-FAP regulatory axis that drives fibroblast activation and intestinal fibrosis; fibroblast-specific Prrx1 deletion (Col1a2-Cre;Prrx1fl/fl) mitigates DNBS-induced intestinal fibrosis.\",\n      \"method\": \"Single-cell RNA-seq, ChIP-seq, dual-luciferase reporter assays, conditional knockout mouse model, colon proteomics\",\n      \"journal\": \"Journal of nanobiotechnology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-seq and reporter assays with conditional KO validation, single lab\",\n      \"pmids\": [\"41350883\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Mechanical stimulation enhances release of active TGF-β1, which promotes migration of Prrx1+ cells via ciliary TGF-β signaling; inhibition of TGF-β signaling, knockdown of Pallidin (blocking TGFβR2 translocation to primary cilia), or deletion of Ift88 in Prrx1+ cells all abolish mechanics-induced Prrx1+ cell migration.\",\n      \"method\": \"Single-cell RNA sequencing, in vivo mechanical stimulation models, TGFβ inhibition, Pallidin knockdown, Ift88 conditional deletion in Prrx1+ cells, migration assays\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epistasis via multiple genetic and pharmacological interventions with defined mechanosensing pathway, single lab\",\n      \"pmids\": [\"35475783\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PRRX1A isoform transcriptionally activates TGF-β expression (shown by correlation with TGF-β and TGF-β/TGFβR signaling), and PRRX1A directly binds and stabilizes SOX2 protein, promoting cancer stem cell sphere formation and self-renewal in non-small cell lung cancer.\",\n      \"method\": \"Isoform-specific overexpression and knockdown, CSC functional assays, co-immunoprecipitation (PRRX1A-SOX2 binding), in vivo mouse models\",\n      \"journal\": \"Translational lung cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — co-IP of PRRX1A-SOX2 with isoform-specific functional characterization, single lab\",\n      \"pmids\": [\"32676335\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Pre-metastatic niche-derived SDF-1 downregulates Prrx1 through STAT3 signaling in hepatocellular carcinoma cells, which in turn increases CXCR4 expression, promoting organ colonization; loss of Prrx1 was negatively correlated with increased CXCR4 in metastatic sites.\",\n      \"method\": \"Prrx1 shRNA knockdown, SDF-1 stimulation, STAT3 pathway inhibition, in vivo xenograft/metastasis assays\",\n      \"journal\": \"Journal of experimental & clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epistasis via pharmacological inhibition and genetic KD in vivo, single lab\",\n      \"pmids\": [\"31752959\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Nicotine inhibits Prrx1 expression in pituitary stem/progenitor cells through epigenetic regulation (first intron hypermethylation of the Prrx1 gene detected by bisulfite sequencing), leading to a delayed supply of GH-producing cells.\",\n      \"method\": \"In vivo nicotine exposure in young rats, bisulfite sequencing, RT-PCR, immunohistochemistry\",\n      \"journal\": \"Growth hormone & IGF research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — bisulfite sequencing demonstrates epigenetic regulation with in vivo functional consequence, single lab\",\n      \"pmids\": [\"32146343\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Heterozygous missense variants within the PRRX1 homeodomain cause abnormal nuclear localization of the PRRX1 protein, establishing that homeodomain missense mutations impair nuclear targeting as a pathogenic mechanism in craniosynostosis.\",\n      \"method\": \"Immunofluorescence analysis of nuclear localization of wild-type vs. mutant PRRX1 proteins in patient-derived and transfected cells\",\n      \"journal\": \"Genetics in medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization experiment with functional consequence linking missense mutations to nuclear import defect\",\n      \"pmids\": [\"37154149\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PRRX1 promotes ANXA6 expression transcriptionally (confirmed by ChIP-PCR and dual-luciferase assay), and ANXA6 enhances PKCα/EGFR complex formation, inhibiting EGFR phosphorylation and downstream AKT and ERK1/2, thereby increasing cisplatin sensitivity in bladder cancer.\",\n      \"method\": \"ChIP-PCR, dual-luciferase assay, co-immunoprecipitation (ANXA6-PKCα-EGFR complex), mass spectrometry, immunofluorescence\",\n      \"journal\": \"Life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and Co-IP with mechanistic pathway dissection, single lab\",\n      \"pmids\": [\"39528080\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PRRX1 is a paired-related homeodomain transcription factor that directly binds gene promoters (including TGF-β1, Sox9, Osx, ABCC1, MMP13, IL-6, FAP, and FKBP5) to regulate target gene transcription; it physically interacts with co-regulators (FOXM1, TOP2A, DNMT3A, SOX2) and SRF at CArG elements, acts as a master regulator of EMT (inducing migration/invasion while uncoupling EMT from stemness), drives fibroblast-to-myofibroblast conversion via TGF-β/super-enhancer remodeling, functions as a mesenchymal stem cell marker and fate regulator for bone/adipose/dermal lineages, and suppresses adipogenesis by sustaining TGFβ ligand expression, with NUP98-PRRX1 fusion oncoproteins recruiting HDAC1 via FG repeats to act as dual transcriptional activators/repressors in leukemia.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"PRRX1 is a paired-related homeodomain transcription factor that serves as a master regulator of mesenchymal cell identity, controlling epithelial-mesenchymal transition (EMT), fibroblast activation, and mesenchymal stem cell fate across bone, adipose, and dermal lineages. PRRX1 directly binds promoters of diverse target genes—including TGF-β1, Sox9, Osx, FAP, MMP13, IL-6, ABCC1, FKBP5, TNC, COL6A3, OLR1, and ANXA6—to activate or repress transcription, and physically interacts with co-regulators such as SRF, FOXM1, TOP2A, DNMT3A, and SOX2 to shape context-dependent transcriptional outputs [PMID:9343429, PMID:30705403, PMID:34214250, PMID:35589735, PMID:38448751]. Through its two isoforms (PRRX1a and PRRX1b), it differentially regulates migration versus invasion, suppresses adipogenesis via sustained TGF-β ligand expression, drives fibroblast-to-myofibroblast conversion through super-enhancer remodeling, and controls cancer-associated fibroblast plasticity that influences chemoresistance [PMID:23201163, PMID:23250756, PMID:23355395, PMID:33007300, PMID:35589735]. Loss-of-function mutations in the PRRX1 homeodomain cause familial atrial fibrillation through impaired transactivation of cardiac target genes ISL1 and SHOX2, and homeodomain missense variants cause craniosynostosis through defective nuclear localization [PMID:34845933, PMID:37154149].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Establishing PRRX1 as a transcription factor that activates SRE-dependent gene expression through physical interaction with SRF resolved how a homeodomain protein could regulate serum-responsive genes without acting through enhanced SRF DNA binding.\",\n      \"evidence\": \"Systematic homeodomain mutagenesis and in vivo transcription assays identifying SRF-contact residues on helices 1/2; separate competition assays showing PRRX1 does not overcome YY1-mediated CArG repression\",\n      \"pmids\": [\"9343429\", \"9174170\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous genomic targets of PRRX1-SRF complexes not identified\", \"Crystal structure of PRRX1-SRF complex unavailable\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Identification of the NUP98-PRRX1 fusion in AML established that the PRRX1 homeodomain could be co-opted into an oncogenic transcription factor when fused to the NUP98 transactivation domain.\",\n      \"evidence\": \"Molecular cloning and breakpoint sequencing of t(1;11)(q23;p15) in AML patient samples\",\n      \"pmids\": [\"10397741\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No functional reconstitution of transformation at this stage\", \"Endogenous target genes of the fusion not identified\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Demonstrating that NUP98-PRRX1 recruits HDAC1 via FG repeats to repress PMX1/SRF-mediated transcription, while also binding CBP, revealed how the fusion functions as a dual activator/repressor—a key mechanistic distinction from wild-type PRRX1.\",\n      \"evidence\": \"Co-immunoprecipitation of HDAC1 and CBP with NUP98-PRRX1, luciferase reporter assays showing trans-repression of c-FOS SRE\",\n      \"pmids\": [\"16651408\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide targets of dual regulation not mapped\", \"Relative contribution of activation vs. repression to leukemogenesis unclear\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Showing that NUP98-PMX1 leukemogenesis requires the GLFG domain and homeodomain DNA binding but is independent of SRF interaction clarified that the fusion transforms through homeodomain-directed target gene dysregulation rather than SRF pathway hijacking.\",\n      \"evidence\": \"Strategic homeodomain mutations disrupting SRF interaction vs. DNA binding tested in retroviral transduction of murine progenitors and in vivo leukemia models; Meis1 collaboration demonstrated\",\n      \"pmids\": [\"18604245\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets driving transformation not identified\", \"Mechanism of Meis1 cooperation unresolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identifying PRRX1 as an obligate mediator of TNF-α-induced suppression of osteoblast differentiation through direct binding to the Osterix promoter placed PRRX1 as a transcriptional repressor in inflammatory bone biology.\",\n      \"evidence\": \"ChIP confirming PRRX1 binding to Osx promoter, EMSA, siRNA rescue abolishing TNF-mediated Osx suppression in preosteoblasts\",\n      \"pmids\": [\"20683885\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PRRX1 directly recruits co-repressors to the Osx promoter unknown\", \"In vivo bone phenotype of PRRX1 loss in inflammatory setting not tested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Two landmark studies revealed PRRX1 as both an EMT inducer that uncouples migration/invasion from stemness in cancer and a suppressor of adipogenesis through TGF-β ligand maintenance, establishing its dual role in cell identity and lineage fate decisions.\",\n      \"evidence\": \"In vivo metastasis assays showing PRRX1 loss enables colonization with MET and stem cell property acquisition; stable knockdown/overexpression with adipogenesis assays and TGF-β inhibitor rescue\",\n      \"pmids\": [\"23201163\", \"23250756\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Chromatin-level mechanism of EMT gene regulation by PRRX1 not defined\", \"Whether TGF-β2/3 promoters are direct PRRX1 targets not shown by ChIP\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstrating isoform-specific functions—PRRX1b binding the Sox9 promoter to regulate acinar-ductal metaplasia while PRRX1a and PRRX1b differentially control migration vs. invasion—revealed that alternative C-termini direct distinct transcriptional programs.\",\n      \"evidence\": \"Isoform-specific overexpression, Sox9 promoter binding assays, Prrx1creERT2-IRES-GFP lineage tracing in pancreas\",\n      \"pmids\": [\"23355395\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for isoform-specific DNA target selectivity unknown\", \"Genome-wide isoform-specific binding profiles not generated\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Linking PRRX1 to atrial electrophysiology—showing that PRRX1 suppression shortens atrial action potential duration and that a common SNP in a PRRX1 enhancer alters its expression—connected this developmental transcription factor to atrial fibrillation susceptibility.\",\n      \"evidence\": \"hESC-derived cardiomyocyte and zebrafish knockdown with electrophysiological recordings; enhancer reporter assays validating rs577676 function\",\n      \"pmids\": [\"28974514\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct cardiac transcriptional targets of PRRX1 mediating action potential regulation not identified at this stage\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identifying FOXM1 as a direct physical partner of PRRX1 (through Co-IP and domain mapping) demonstrated that PRRX1 cooperates with non-homeodomain transcription factors beyond SRF to regulate target gene programs including DNA damage response.\",\n      \"evidence\": \"Reciprocal Co-IP with domain deletion mapping (PRRX1 aa 200–222 to FOXM1 Forkhead domain), luciferase reporters, loss-of-function rescue in pancreatic cancer cells\",\n      \"pmids\": [\"30705403\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide co-occupancy of PRRX1-FOXM1 not mapped\", \"Structural basis of the interaction not resolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Revealing that PRRX1 controls cancer-associated fibroblast plasticity—switching between dormant and activated myofibroblastic states—and that Prrx1-deficient CAFs constitutively secrete HGF to drive tumor subtype switching and chemoresistance established PRRX1 as a stromal fate regulator in the tumor microenvironment.\",\n      \"evidence\": \"Prrx1 genetic depletion in PDAC mouse model, CAF-tumor organoid co-culture, gene expression subtype analysis\",\n      \"pmids\": [\"33007300\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets mediating CAF state switching not fully catalogued\", \"Whether PRRX1 regulates HGF promoter directly not determined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Multiple studies converged on PRRX1 as a direct promoter-binding activator of TGF-β1 (in glioma), a DNMT3A-recruiting epigenetic silencer of PROM1 (isoform-specific, PRRX1b only), and an upstream controller of MET via the PITX2/miR-200 axis, broadening the repertoire of PRRX1 effector mechanisms beyond simple transcriptional activation.\",\n      \"evidence\": \"ChIP for TGF-β1 promoter binding with TGF-β1 silencing rescue; Co-IP of PRRX1b-DNMT3A with bisulfite sequencing of PROM1 promoter; epistasis experiments in HCC dissecting PRRX1→PITX2→miR-200→E-cadherin pathway\",\n      \"pmids\": [\"34131109\", \"34214250\", \"33587761\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether DNMT3A recruitment is genome-wide or locus-specific unknown\", \"PRRX1b structural determinants for DNMT3A selectivity not mapped\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identification of PRRX1 loss-of-function mutations (p.Gln107* and p.Arg146Ile) as causes of familial atrial fibrillation, with diminished transactivation of ISL1 and SHOX2, established PRRX1 haploinsufficiency as a Mendelian arrhythmia mechanism.\",\n      \"evidence\": \"Whole-exome sequencing in AF families, Sanger confirmation, luciferase reporter assays showing reduced transactivation and promoter binding of mutant PRRX1\",\n      \"pmids\": [\"34845933\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Independent replication in additional families needed\", \"In vivo electrophysiological validation of these specific mutations not performed\", \"Whether ISL1/SHOX2 are direct or indirect targets not resolved by ChIP\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Genome-wide super-enhancer profiling established PRRX1 as a master transcription factor that remodels the super-enhancer landscape to convert fibroblasts to myofibroblasts via TGF-β signaling, and fibroblast-specific Prrx1 depletion induced sustained remission of chemotherapy-resistant tumors, demonstrating stromal PRRX1 as a therapeutic vulnerability.\",\n      \"evidence\": \"ChIP-seq for super-enhancer marks, fibroblast-specific genetic depletion in genetically engineered mouse models of PDAC\",\n      \"pmids\": [\"35589735\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which specific super-enhancers are essential for myofibroblast conversion not individually validated\", \"Pharmacological targeting strategy not established\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Lineage tracing identified Prrx1-expressing cells as rare adult mesenchymal stem cells for bone, adipose, and dermis, and as a pro-fibrotic fibroblast subpopulation in wound repair, resolving their in vivo identity and tissue-regenerative functions.\",\n      \"evidence\": \"Knock-in Cre/CreERT2 lineage tracing, cell depletion, transplantation assays, single-cell RNA-seq in dermal wound models and homeostatic tissues\",\n      \"pmids\": [\"36456880\", \"33176144\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcriptional targets maintaining stemness vs. driving fibrosis in Prrx1+ cells not distinguished\", \"Human in vivo equivalence of Prrx1+ stem cell population not demonstrated\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstrating that homeodomain missense variants cause aberrant PRRX1 nuclear localization linked homeodomain integrity to nuclear import as a pathogenic mechanism in craniosynostosis.\",\n      \"evidence\": \"Immunofluorescence of wild-type vs. mutant PRRX1 in patient-derived and transfected cells\",\n      \"pmids\": [\"37154149\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Nuclear import machinery interacting with PRRX1 homeodomain not identified\", \"Rescue experiments restoring nuclear localization not performed\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"ChIP-validated direct binding of PRRX1 to multiple new promoter targets (TNC, FAP, ANXA6, OLR1) and placement downstream of Twist1 in fibrosis cascades expanded the PRRX1 regulon and solidified its role as a central node in organ fibrosis across kidney, intestine, and heart.\",\n      \"evidence\": \"ChIP assays for Twist1→Prrx1 promoter and Prrx1→TNC promoter with fibroblast-specific Twist1 KO; ChIP-seq and conditional Prrx1 KO for FAP in intestinal fibrosis; ChIP-PCR for ANXA6 and OLR1 in cancer models\",\n      \"pmids\": [\"39181396\", \"41350883\", \"39528080\", \"39010054\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Comprehensive genome-wide PRRX1 cistrome across tissue contexts not integrated\", \"Co-factor requirements at each target promoter not systematically defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The genome-wide binding landscape of endogenous PRRX1 across its major biological contexts (mesenchymal stem cells, fibroblasts, cardiomyocytes, cancer) has not been integrated, and the structural basis for isoform-specific partner selection and target gene discrimination remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No crystal or cryo-EM structure of PRRX1 homeodomain with DNA or any partner\", \"Integrated multi-tissue PRRX1 ChIP-seq/CUT&RUN atlas absent\", \"Isoform-specific regulatory mechanisms at the structural level unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [3, 7, 8, 10, 15, 22, 23, 25, 31, 37]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 3, 6, 7, 8, 10, 13, 15, 22, 23, 24, 25, 28, 31, 37]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [6, 18]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [3, 7, 36]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0074160\", \"supporting_discovery_ids\": [3, 7, 8, 10, 13, 15, 22, 23, 24, 25, 28, 31, 37]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [6, 10, 15, 22, 27, 30]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [7, 8, 17]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [1, 2, 5]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"SRF\",\n      \"FOXM1\",\n      \"DNMT3A\",\n      \"SOX2\",\n      \"TOP2A\",\n      \"HDAC1\",\n      \"CBP\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}